Literature DB >> 24951349

Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson.

L Fournier1, S Ammari2, R Thiam3, C-A Cuénod3.   

Abstract

Most methods define a limited number of "target" lesions to be measured and other "non-target" lesions to be evaluated qualitatively. RECIST criteria are the most widely used although other criteria have been proposed that are derived from them based on size alone, or size and attenuation. Modified RECIST (mRECIST) criteria only concern hepatocellular carcinoma and only take into account the viable portion (enhanced after injection during the arterial phase). Cheson criteria are more complex as target lesions are defined differently depending on the organ (lymph nodes, liver or spleen, other organs), and involve both CT and PET scans, as well as the clinical examination and bone marrow biopsy.
Copyright © 2014 Éditions françaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  CT; Hepatocellular carcinoma; MRI; RECIST criteria; Tumour

Mesh:

Year:  2014        PMID: 24951349     DOI: 10.1016/j.diii.2014.05.002

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  18 in total

1.  Prediction of Tumor Control in 90Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics.

Authors:  Yuni K Dewaraja; Theresa Devasia; Ravi K Kaza; Justin K Mikell; Dawn Owen; Peter L Roberson; Matthew J Schipper
Journal:  J Nucl Med       Date:  2019-05-30       Impact factor: 10.057

2.  Evaluation of response after SBRT for liver tumors.

Authors:  Raphael Tétreau; Carmen Llacer; Olivier Riou; Emmanuel Deshayes
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-30

3.  mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study.

Authors:  S Mazzeo; R Cervelli; R Elisei; G Tarantini; C Cappelli; E Molinaro; D Galleri; L De Napoli; C Comite; R Cioni; P Vitti; D Caramella
Journal:  J Endocrinol Invest       Date:  2018-04-23       Impact factor: 4.256

4.  Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.

Authors:  Erel Joffe; Yan Leyfman; Esther Drill; Sridevi Rajeeve; Andrew D Zelenetz; M Lia Palomba; Craig H Moskowitz; Carol Portlock; Ariela Noy; Steven M Horwitz; John F Gerecitano; Alison Moskowitz; Paul Hamlin; Matthew J Matasar; Anita Kumar; Connie L Batlevi; Anas Younes; David J Straus
Journal:  Blood Adv       Date:  2021-01-26

5.  Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study.

Authors:  Marta Campos; Isabel Candelária; Nickolas Papanikolaou; Adélia Simão; Carlos Ferreira; Georgios C Manikis; Filipe Caseiro-Alves
Journal:  GE Port J Gastroenterol       Date:  2019-02-18

6.  Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.

Authors:  Mark Yarchoan; Parul Agarwal; Augusto Villanueva; Shuyun Rao; Laura A Dawson; Josep M Llovet; Richard S Finn; John D Groopman; Hashem B El-Serag; Satdarshan P Monga; Xin Wei Wang; Michael Karin; Robert E Schwartz; Kenneth K Tanabe; Lewis R Roberts; Preethi H Gunaratne; Allan Tsung; Kimberly A Brown; Theodore S Lawrence; Riad Salem; Amit G Singal; Amy K Kim; Atoosa Rabiee; Linda Resar; Yujin Hoshida; Aiwu Ruth He; Kalpana Ghoshal; Patrick B Ryan; Elizabeth M Jaffee; Chandan Guha; Lopa Mishra; C Norman Coleman; Mansoor M Ahmed
Journal:  Cancer Res       Date:  2019-09-01       Impact factor: 12.701

7.  Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.

Authors:  Rajesh Kaldate; Robin Kate Kelley; Tim Meyer; Lorenza Rimassa; Philippe Merle; Joong-Won Park; Thomas Yau; Stephen L Chan; Jean-Frederic Blanc; Vincent C Tam; Albert Tran; Vincenzo Dadduzio; David W Markby; Ann-Lii Cheng; Anthony B El-Khoueiry; Ghassan K Abou-Alfa
Journal:  Clin Cancer Res       Date:  2020-07-07       Impact factor: 12.531

8.  Blood Flow Diversion Within Hepatocellular Carcinoma (HCC) after Selective Occlusion of Feeding Arteries (SOFA) and Feasibility of Utilizing the SOFA Technique in Transarterial Chemoembolization (SOFA-TACE).

Authors:  Simon Chun Ho Yu
Journal:  Cardiovasc Intervent Radiol       Date:  2021-10-03       Impact factor: 2.740

9.  Therapeutic strategies for hepatocellular carcinoma: new advances and challenges.

Authors:  Sílvia Vilarinho; Tamar Taddei
Journal:  Curr Treat Options Gastroenterol       Date:  2015-06

10.  The Necrosis-Avid Small Molecule HQ4-DTPA as a Multimodal Imaging Agent for Monitoring Radiation Therapy-Induced Tumor Cell Death.

Authors:  Marieke A Stammes; Azusa Maeda; Jiachuan Bu; Deborah A Scollard; Iris Kulbatski; Philip J Medeiros; Riccardo Sinisi; Elena A Dubikovskaya; Thomas J A Snoeks; Ermond R van Beek; Alan B Chan; Clemens W G M Löwik; Ralph S DaCosta
Journal:  Front Oncol       Date:  2016-10-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.